Sharenet Sites 
Sharenet Sites
Transactions by persons discharging managerial responsibilities and persons closely associated with them
Mediclinic International plc
(Incorporated in England and Wales)
Company Number: 08338604
LSE Share Code: MDC
JSE Share Code: MEI
NSX Share Code: MEP
ISIN: GB00B8HX8Z88
LEI: 2138002S5BSBIZTD5I60
(“Mediclinic”, the “Company” or the “Group”)
30 May 2018
NOTIFICATION OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL
RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM
On 24 and 25 May 2018, Mr Danie Meintjes, Chief Executive Officer of Mediclinic International plc, sold
a total of 49 423 shares in the Company, being the shares awarded to Mr Meintjes in 2014 under the
Mediclinic International Limited Forfeitable Share Plan, which vested on 31 May 2017. Mr Meintjes
retained the totality of the shares at the time but has now disposed of them to cover personal tax
liabilities. Mr Meintjes continues to hold 123 900 shares in the Company.
The notification below is made in accordance with Articles 19.1 and 19.3 of the Market Abuse
Regulation.
1. Details of PDMR / person closely associated with them (“PCA”)
a) Name Mr Daniël Petrus Meintjes
2. Reason for the notification
a) Position / status Chief Executive Officer of the Company
b) Initial notification / Initial Notification
amendment
3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or
auction monitor
a) Name Mediclinic International plc
b) LEI 2138002S5BSBIZTD5I60
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each
type of transaction; (iii) each date; and (iv) each place where transactions have been
conducted
a) Description of the Ordinary Shares
financial instrument
Identification Code GB00B8HX8Z88
b) Nature of the Sale of shares awarded in 2014 under the Mediclinic
transaction International Limited Forfeitable Share Plan, which vested on
31 May 2017
c) Price(s) and
volume(s) Price(s) Volume(s)
ZAR 110.01 per share 17 423
d) Aggregated
information
Aggregated volume 17 423
Price ZAR 110.01
e) Date of the 24 May 2018
transaction
f) Place of the Johannesburg Stock Exchange
transaction
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each
type of transaction; (iii) each date; and (iv) each place where transactions have been
conducted
a) Description of the Ordinary Shares
financial instrument
Identification Code GB00B8HX8Z88
b) Nature of the Sale of shares awarded in 2014 under the Mediclinic
transaction International Limited Forfeitable Share Plan, which vested on
31 May 2017
c) Price(s) and
volume(s) Price(s) Volume(s)
ZAR 107.01 per share 32 000
d) Aggregated
information
Aggregated volume 32 000
Price ZAR 107.01
e) Date of the 25 May 2018
transaction
f) Place of the Johannesburg Stock Exchange
transaction
About Mediclinic International plc
Mediclinic is an international private healthcare services group with operating divisions in Switzerland,
Southern Africa (South Africa and Namibia) and the United Arab Emirates. Its core purpose is to
enhance the quality of life of patients by providing acute care, specialist-orientated, multi-disciplinary
healthcare services. Mediclinic also holds a 29.9% interest in Spire Healthcare Group plc, an LSE-listed
and UK-based private healthcare group.
Mediclinic comprises 75 hospitals and 28 clinics. Hirslanden operates 17 private acute care facilities
and 4 clinics in Switzerland with more than 1 800 inpatient beds; Mediclinic Southern Africa operates
49 hospitals and 2 day clinics throughout South Africa and 3 hospitals in Namibia with more than 8 100
inpatient beds in total; and Mediclinic Middle East operates 6 hospitals and 22 clinics with more than
700 inpatient beds in the United Arab Emirates.
Mediclinic has a primary listing on the Main Market of the LSE in the United Kingdom, with secondary
listings on the JSE in South Africa and the NSX in Namibia.
For further information, please contact:
Company Secretary, Link Company Matters Limited
Jayne Meacham / Caroline Emmet
+44 (0)20 7954 9569
Investor Relations, Mediclinic International plc
James Arnold, Head of Investor Relations
ir@mediclinic.com
+44 (0)20 3786 8181
Media queries
FTI Consulting
Brett Pollard/Debbie Scott – UK
+44 (0)20 3727 1000
Sherryn Schooling – South Africa
+27 (0)21 487 9000
Registered address: 6th Floor, 65 Gresham Street, London, EC2V 7NQ, United Kingdom
Website: www.mediclinic.com
Joint corporate brokers: Morgan Stanley & Co International plc and UBS Investment Bank
JSE sponsor: Rand Merchant Bank (A division of FirstRand Bank Limited)
NSX sponsor: Simonis Storm Securities (Pty) Ltd
Date: 30/05/2018 04:00:00 Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE').
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct,
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
information disseminated through SENS.
